UBS Group
IMNM icon

UBS Group’s Immunome IMNM Stock Holding History

UBS Group’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.96M Sell
328,493
-104,419
-24% -$2.23M ﹤0.01% 3830
2026
Q1 		$9.47M Buy
432,912
+125,718
+41% +$2.8M ﹤0.01% 3419
2025
Q4 		$6.6M Sell
307,194
-276,748
-47% -$4.86M ﹤0.01% 3738
2025
Q3 		$6.84M Buy
583,942
+158,027
+37% +$1.57M ﹤0.01% 3705
2025
Q2 		$3.96M Buy
425,915
+81,864
+24% +$671K ﹤0.01% 4114
2025
Q1 		$2.32M Buy
344,051
+155,854
+83% +$1.5M ﹤0.01% 4586
2024
Q4 		$2M Buy
188,197
+108,957
+138% +$1.32M ﹤0.01% 4714
2024
Q3 		$1.16M Buy
79,240
+1,557
+2% +$22.1K ﹤0.01% 4525
2024
Q2 		$940K Buy
77,683
+53,032
+215% +$830K ﹤0.01% 4473
2024
Q1 		$608K Buy
+24,651
New +$500K ﹤0.01% 5034
2023
Q4 		– Sell
-14
Closed -$117 – 9583
2023
Q3 		$117 Sell
14
-1,044
-99% -$7.67K ﹤0.01% 8848
2023
Q2 		$8.37K Buy
1,058
+1,044
+7,457% +$5.71K ﹤0.01% 7244
2023
Q1 		$70 Sell
14
-460
-97% -$2.25K ﹤0.01% 9291
2022
Q4 		$1.05K Sell
474
-14,797
-97% -$59.6K ﹤0.01% 9973
2022
Q3 		$68K Buy
15,271
+13,943
+1,050% +$65.4K ﹤0.01% 6056
2022
Q2 		$4K Buy
1,328
+1,208
+1,007% +$4.39K ﹤0.01% 9076
2022
Q1 		$1K Sell
120
-2,371
-95% -$17.7K ﹤0.01% 9880
2021
Q4 		$32K Buy
2,491
+2,477
+17,693% +$44.2K ﹤0.01% 7327
2021
Q3 		$0 Sell
14
-1,356
-99% -$23.7K ﹤0.01% 9784
2021
Q2 		$24K Buy
1,370
+922
+206% +$20.4K ﹤0.01% 7142
2021
Q1 		$15K Sell
448
-586
-57% -$14.6K ﹤0.01% 7627
2020
Q4 		$10K Buy
+1,034
New +$12.1K ﹤0.01% 7486

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

UBS Group's IMNM Position: Q2 2026 in Review

UBS Group reduced its Immunome (IMNM) stake by 24% in Q2 2026, selling an estimated $2.23M and leaving 328,493 shares worth $6.96M. The position accounts for ﹤0.01% of the portfolio, ranked #3830.

UBS Group first reported a position in IMNM in Q4 2020 and has held it in 22 quarters since. The position peaked at $9.47M in Q1 2026. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • UBS Group held 328,493 shares of Immunome worth $6.96M as of Q2 2026.
  • UBS Group sold 104,419 Immunome shares in Q2 2026, an estimated $2.23M.
  • Immunome made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3830 holding.
  • UBS Group first reported a position in Immunome in Q4 2020 and has held it in 22 quarters since.
  • UBS Group's Immunome position peaked at $9.47M in Q1 2026.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.